The guidance implements provisions
added to the Federal Food, Drug, and Cosmetic Act (FD&C Act) in
the Drug Quality and Security Act (DQSA), which created a statutory
category of "outsourcing facilities" that compound human drugs.
Section 503B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
353b) requires compounders that register with FDA as outsourcing
facilities to report adverse events to FDA. Specifically, under
section 503B(b)(5) of the FD&C Act, an outsourcing facility
must submit adverse event reports to FDA "in accordance with the
content and format requirements established through guidance or
regulation under section 310.305 of title 21, Code of Federal
Regulations (or any successor regulations)." We are requesting OMB
approval of the information collection resulting from adverse event
reporting for outsourcing facilities.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.